Tresiba® trial shows that people with type 2 diabetes who avoid severe hypoglycaemia have a reduced risk of death
Bangalore, 16 September 2017 – Novo Nordisk today announced new analyses from the DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days after an event and two and a half-fold higher anytime following …